Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.
Mühlbacher J, Jilma B, Wahrmann M, Bartko J, Eskandary F, Schörgenhofer C, Schwameis M, Parry GC, Gilbert JC, Panicker S, Böhmig GA. Mühlbacher J, et al. Among authors: wahrmann m. Transplantation. 2017 Oct;101(10):2410-2418. doi: 10.1097/TP.0000000000001804. Transplantation. 2017. PMID: 28926521 Free PMC article. Clinical Trial.
Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.
Wahrmann M, Mühlbacher J, Marinova L, Regele H, Huttary N, Eskandary F, Cohen G, Fischer GF, Parry GC, Gilbert JC, Panicker S, Böhmig GA. Wahrmann M, et al. Am J Transplant. 2017 Sep;17(9):2300-2311. doi: 10.1111/ajt.14256. Epub 2017 Mar 31. Am J Transplant. 2017. PMID: 28251805 Free PMC article.
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC, Halloran PF, Böhmig GA. Eskandary F, et al. Among authors: wahrmann m. Am J Transplant. 2018 Apr;18(4):916-926. doi: 10.1111/ajt.14528. Epub 2017 Oct 31. Am J Transplant. 2018. PMID: 28980446 Free article. Clinical Trial.
Novel Approaches to Block Complement.
Böhmig GA, Wahrmann M, Eskandary F, Rostaing L. Böhmig GA, et al. Among authors: wahrmann m. Transplantation. 2018 Nov;102(11):1837-1843. doi: 10.1097/TP.0000000000002267. Transplantation. 2018. PMID: 29870459 Review.
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F, Dürr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, Firbas C, Mühlbacher J, Bond G, Halloran PF, Chong E, Jilma B, Böhmig GA. Eskandary F, et al. Among authors: wahrmann m. Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6. Trials. 2019. PMID: 30635033 Free PMC article.
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA. Doberer K, et al. Among authors: wahrmann m. J Am Soc Nephrol. 2021 Mar;32(3):708-722. doi: 10.1681/ASN.2020071106. Epub 2020 Dec 18. J Am Soc Nephrol. 2021. PMID: 33443079 Free PMC article. Clinical Trial.
74 results